MedTrace Logo

ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

NCT04082897 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-05-28

No results posted yet for this study

Summary

This study is a multicenter, open-label, uncontrolled, phase II trial aimed to establish the safety and tolerability of venetoclax, atezolizumab and obinutuzumab combination in Richter Transformation of CLL.

Conditions

  • CLL Transformation

Interventions

DRUG

Obinutuzumab 25 MG/ML [Gazyva]

Obinutuzumab will be administered from C1 to C8

DRUG

Atezolizumab 60 MG/ML [Tecentriq]

Atezolizumab will be administered iv from C1 to C18

DRUG

Venetoclax Oral Tablet

Venetoclax will be administered from day 15 cycle 1) until day 21 of cycle 35

Sponsors & Collaborators

  • Niguarda Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-04
Primary Completion
2026-09-30
Completion
2026-12-31

Countries

  • Italy
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04082897 on ClinicalTrials.gov